Sriram Ryali Acquires 17,360 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) Stock

Caribou Biosciences, Inc. (NASDAQ:CRBU) CFO Sriram Ryali purchased 17,360 shares of the stock in a transaction dated Wednesday, January 29th. The shares were purchased at an average price of $1.42 per share, with a total value of $24,651.20. Following the completion of the acquisition, the chief financial officer now owns 17,360 shares of the company’s stock, valued at approximately $24,651.20. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Caribou Biosciences Trading Down 2.2 %

Shares of CRBU opened at $1.31 on Friday. The firm has a market capitalization of $118.62 million, a P/E ratio of -0.79 and a beta of 2.34. The stock’s fifty day simple moving average is $1.78 and its 200 day simple moving average is $1.98. Caribou Biosciences, Inc. has a twelve month low of $1.30 and a twelve month high of $8.33.

Caribou Biosciences (NASDAQ:CRBU) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.06. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The business had revenue of $2.02 million for the quarter, compared to analyst estimates of $3.37 million. Sell-side analysts predict that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently issued reports on CRBU. Citigroup decreased their target price on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, November 26th. Bank of America lowered their price objective on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $9.00 target price on shares of Caribou Biosciences in a research report on Friday, November 15th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $10.33.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CRBU. American Century Companies Inc. raised its stake in shares of Caribou Biosciences by 15.2% in the 2nd quarter. American Century Companies Inc. now owns 125,029 shares of the company’s stock valued at $205,000 after acquiring an additional 16,530 shares during the period. Dimensional Fund Advisors LP raised its position in Caribou Biosciences by 25.7% in the second quarter. Dimensional Fund Advisors LP now owns 2,623,283 shares of the company’s stock valued at $4,302,000 after purchasing an additional 536,162 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Caribou Biosciences during the second quarter worth about $2,432,000. Hsbc Holdings PLC grew its stake in shares of Caribou Biosciences by 476.4% in the second quarter. Hsbc Holdings PLC now owns 80,867 shares of the company’s stock valued at $129,000 after buying an additional 66,838 shares in the last quarter. Finally, AQR Capital Management LLC purchased a new stake in shares of Caribou Biosciences during the 2nd quarter valued at about $30,000. 77.51% of the stock is owned by institutional investors and hedge funds.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.